You are here: Industry Insights > Market News > NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

chinadailyAugust 21, 2019

Tag: NMPA , Announcement , Drug Standards

Favorites

To promote the consistency evaluation of the quality and efficacy of generic drugs, and clarify the relationship between the registration standards of generic drugs and the national drug standards such as the Pharmacopoeia of the People's Republic of China, on August 2, 2019, NMPA issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content,

please email: Julia.Zhang@ubmsinoexpo.com to delete.

Previous:Nabriva’s bacterial pneumonia drug gets US regulatory approval

Next:NMPA Issued the Notice on Expanding the Pilot of the Medical Device Registrant System

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>